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Review Article
Understanding the Epidemiology of Heart Failure to Improve
Management Practices: An Asia-Pacific Perspective
JEYAMALAR RAJADURAI, MBBS,1 HUNG-FAT TSE, MBBS, MD, PhD,2 CHAO-HUNG WANG, MD, PhD,3
NING-I YANG, MBChB,3 JINGMIN ZHOU, MD,4 AND DAVID SIM, MBBS5
Subang Jaya, Malaysia; Hong Kong and Shanghai, China; Taoyuan, Taiwan; and Singapore
ABSTRACT
Heart failure (HF) is a major global healthcare problem with an estimated prevalence of approximately 26
million. In Asia-Pacific regions, HF is associated with a significant socioeconomic burden and high rates
of hospital admission. Epidemiological data that could help to improve management approaches to address
this burden in Asia-Pacific regions are limited, but suggest patients with HF in the Asia-Pacific are younger
and have more severe signs and symptoms of HF than those of Western countries. However, local guide-
lines are based largely on the European Society of Cardiology and American College of Cardiology Foundation/
American Heart Association guidelines, which draw their evidence from studies where Western patients
form the major demographic and patients from the Asia-Pacific region are underrepresented. Furthermore,
regional differences in treatment practices likely affect patient outcomes. In the following review, we examine
epidemiological data from existing regional registries, which indicate that these patients represent a dis-
tinct subpopulation of patients with HF. In addition, we highlight that patients with HF are under-treated
in the region despite the existence of local guidelines. Finally, we provide suggestions on how data can be
enriched throughout the region, which may positively affect local guidelines and improve management practices.
(J Cardiac Fail 2017;23:327–339)
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Heart failure (HF) has an estimated global prevalence of ap-
proximately 26 million and is a leading cause of morbidity and
mortality and therefore is a global health care problem.1,2 InAsia-
Pacific regions, HF is associated with a significant socioeconomic
burden, representing a major cause of hospital admissions and
readmissions, loss of work and productivity, and death.3–6 In
Western countries, extensive information is available on the epi-
demiology and management of HF because of established disease-
specific registries7–12 and clinical guidelines.13,14 In contrast, reliable
data on disease prevalence and incidence of HF in Asia-Pacific
regions are lacking and it is likely that region-wide differences
in treatment practices affect patient outcomes.An accurate account
of HF in this region is critical and has the potential to influence
clinical management, which may improve patient outcomes over
the short and long term.
In this narrative review, current understanding of the epi-
demiology of HF in Asia-Pacific regions is discussed (supported
by data from local disease registries and regional clinical trials)
to characterize how patients from these regions may differ from
Western countries. We review current clinical management prac-
tices and local guidelines throughout the region, highlighting
ways in which regional data and management practices can be
enhanced to improve patient outcomes.
Search Strategy
We searched PubMed for English-language articles re-
porting on the epidemiological data and current management
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practices of adults with HF in Asia-Pacific regions pub-
lished between January 2000 and August 2016 using the
following search criteria: Asia/Asia Pacific, heart failure/
chronic heart failure/acute heart failure (including heart failure
with reduced or preserved ejection fraction). The search results
were first evaluated by title and/or abstract for relevant pub-
lications, particularly registry, observational, and controlled
studies. Full articles were reviewed for those citations iden-
tified for inclusion in the manuscript, the majority of which
were published after 2010. We also examined the official web-
sites of national HF societies to identify local HF guidelines.
The Epidemiology of HF in Asia-Pacific Regions
Prevalence of HF
Approximately 5.7 million (2.2%) adults aged ≥20 years
in the United States have HF.15 In contrast to Western coun-
tries, there are large gaps in information relating to HF inAsia.16
According to the America Heart Association (AHA), current
estimates of HF prevalence in this region range from 1.26%
to 6.7%.15 Looking specifically at individual countries and
areas within Asia, the enormity of the problem becomes clear.
For example, in China alone, approximately 4.2 million people
have HF, whereas in India prevalence estimates vary widely
between 1.3 and 23 million, and in Southeast Asia, 9 million
people are estimated to have HF.17–19 Additionally, based on
the incidence of de novo HF in the United States (10 of 1000
people aged ≥65 years, per year),15 it has been predicted that
more than 0.37 million Japanese individuals aged ≥65 years
will develop new-onset HF in 2025.20 With the aging popu-
lation and the rising prevalence of various cardiovascular (CV)
risk factors, such as hypertension and diabetes, it is evident
that a significant number of people will continue to develop
HF every year in the region.16,21–23 Data available from the
few regional studies indicate a prevalence of HF among hos-
pitalized patients of 3.4% to 6.7%,20,24 and in common with
evidence from Western populations, studies suggest that hos-
pitalization for HF is increasing in the region.25,26 Further detail
by type of HF is required to characterize the region-specific
burden of disease. The following overview provides a summary
of the current epidemiological data of acutely decompen-
sated HF (ADHF) and chronic HF (HF with reduced ejection
fraction [HFrEF] and HF with preserved ejection fraction
[HFpEF]) in the Asia-Pacific.
ADHF
Patients with ADHF commonly present in the emergency
setting and require urgent management. Admission to hos-
pital for ADHF is a powerful predictor of readmission and
postdischarge death in patients with chronic HF.27,28 There-
fore, identification and appropriate management of these
patients is crucial for improving outcomes.
Despite an increase in the prevalence of ADHF, there are
still limited data on its epidemiology, treatment, and prog-
nosis in the Asia-Pacific region. As shown in Table 1, regional
data are available from the Acute Decompensated Heart Failure
Registry-International Asia-Pacific (ADHERE-AP),29 the Thai
Acute Decompensated Heart Failure Registry,30 the Acute De-
compensated Heart Failure Syndromes (ATTEND) registry,31
the Korean Acute Heart Failure registry,32 and the Taiwan
Society of Cardiology—Heart Failure with reduced Ejec-
tion Fraction (TSOC-HFrEF) registry,33 which can be compared
with data from the United States (Acute Decompensated Heart
Failure National Registry [ADHERE]),9 Europe (EuroHeart
Failure Survey II [EHFS II]),34 and the United Kingdom Na-
tional Heart Failure Audit (UKNHFA).35
Overall, patients from the Asia-Pacific were similar to
Western populations, but with some notable differences. With
the exception of patients enrolled in the ATTEND registry
(mean age 73 years), the mean ages of patients with ADHF
in the Asia-Pacific (64–69 years) are lower than that of Western
registries (69–78 years), including the Get With The
Guidelines-HF registry conducted in the United States (2005–
2014; N = 117,761).36 A known history of HF was reported
in similar proportions of patients across the registries
(50%–75%),9,29,30,32,34,35 aside from ATTEND and TSOC-
HFrEF (36% and 40%, respectively).31,33 Overall, in both Asian
and Western registries, a history of ischemic heart disease was
relatively common, although some variation was observed
(31%–58%; Table 1).9,29–35 However, incidence of valvular heart
disease was lower in regional registries compared with the
EHFS II study (Table 1).9,29–35 Intraregional variation in
comorbidity rates could help explain these differences.
Despite some differences in patient characteristics, the
burden of in-hospital morbidity/mortality in the Asia-
Pacific is similar to Western registries. With the exception of
Japanese patients (in which median hospital length of stay
was 21 days), hospital stay was similar in Asia-Pacific reg-
istries compared with ADHERE, EHFS II, and UKNHFA
(median length of stay 6–8 days vs 4–9 days, respectively).9,29–35
The range in length of hospital stay may be a result of dif-
ferences between national health insurance systems, hospital
location (eg, metropolitan vs rural), and hospital teaching/
academic status.37,38 In-hospital mortality in Asia-Pacific
registries was also generally comparable to those in western
registries, despite more patients requiring mechanical ven-
tilation in the Asia-Pacific region (Table 1).
Data from the Acute Study of Clinical Effectiveness of
Nesiritide in Decompensated Heart Failure trial (ASCEND-
HF), covering 5 geographical regions including North America,
Western Europe, and the Asia-Pacific, are consistent with reg-
istry findings; for example, patients from the Asia-Pacific were
younger (62 years) compared with those from North America
(67 years) and Europe (74 years), and hypertension was the
most common comorbidity irrespective of region studied.39
Moreover, median length of hospital stay was 5 days for pa-
tients in the Asia Pacific and North America, but was slightly
greater in Western Europe (8 days).
Chronic HF
Table 2 summarizes the baseline clinical characteristics of
patients enrolled in chronic HF registries across the
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Table 1. Baseline Characteristics and Clinical Treatment of Patients with Acute Decompensated HF Enrolled in Regional Registries
Study ADHERE-AP29 Thai-ADHERE30 ATTEND31 KorAHF32 TSOC-HFrEF33 ADHERE9 EHFS II34/UKNHFA35
Geography (time frame) 8 countries in the Asia-Pacific
(2006–2008)
Thailand
(2006–2007)
Japan
(2007–2012)
Republic of Korea
(2011–2012)
Taiwan
(2013–2014)
United States
(2001–2004)
Europe/United Kingdom
(2004–2005)/(2014–2015)
Patients (n) 10,171 1612* 4842 2066 1509 159,168 3580/56,915 cases (N = 41,461)
Mean age (y) 66 64 73 69 64 72 70/78
Male (%) 57 50 58 55 72 48 61/55
Mean LVEF (%) NR NR NR 40 28 38 38/NR
LVEF <40 (%) 53 40 53 56 100 51 66†/NR
Known HF history 64 67 36 50 40 76 63/NR
NYHA I/II/III/IV (%) NR NR/15/16/70 <2/16/38/44 NR/NR/41/41‡ NR/12/NR§/NR§ NR NR/NR/19/45/37
Etiology (%)
Ischemic heart disease 50 47 31 38 44 58 54/51|| and 40¶
Valvular heart disease NR 19 19 13 8 NR 34/23|| and 33¶
Hypertensive NR 12 18 6 5 NR 11/NR
Cardiomyopathy NR 14 13 15 33** NR 19/NR
Comorbidities (%)
Hypertension 64 65 69 59 35 74 63/52|| and 61¶
Dyslipidemia NR 51 37 NR 20†† NR NR/NR
Diabetes mellitus 45 47 34 36 44 NR 33/33|| and 33¶
Chronic kidney disease 22‡‡ 19§§ NR 14§§ 32 30§§ 17§§/NR
Atrial fibrillation 24 24 40|||| 27 26 31 39‖‖ /21|| and 22¶
COPD NR 8¶¶ 10*** 11*** 11¶¶ 31¶¶ 19/17|| and 19¶
Previous stroke or TIA 13 12 14 15 9 NR 13/NR
In-hospital management (%)
IV diuretics 85 96 76 72 63 87 84/NR
IV nitrates 14 22 35 40 NR 9 38/NR
IV inotropic agents 15 23 19 32 37 8 30†††NR
Mechanical ventilation/intubation 9 20 8 14 13 3 5/NR
Discharge medication (%)
RAAS inhibitors 63 48 70–75‡‡‡ 65 62 83 80§§§/91||
β-blockers 41 25 67 44 60 80 61/86||
Aldosterone antagonists 31 17 40–50‡‡‡ 40 49 33 48/52||
Diuretics NR 73 80–85‡‡‡ NR 82 87 90/98||
(continued on next page)
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Table 1. (Continued)
Study ADHERE-AP29 Thai-ADHERE30 ATTEND31 KorAHF32 TSOC-HFrEF33 ADHERE9 EHFS II34/UKNHFA35
Digitalis 34¶¶¶ 26¶¶¶ 10–15‡‡‡ NR 26 38¶¶¶ 31/23‖¶¶¶
Calcium channel blockers NR NR 25–30‡‡‡ NR NR NR 15/NR
Statins NR NR 30–35‡‡‡ NR NR NR 42/NR
ICD 1.6 3**** 3.4 1.4†††† 1.0†††† NR 1.2††††/NR
CRT 4.2 3**** 2.3 1.3†††† 1.0†††† NR 2.7††††/NR
Outcomes (%)
Median length of hospital stay (d) 6 8 21 8 8 4 9/9
In-hospital mortality (%) 5 6 6 6 2 4 7/9.6
*2041 admissions.
†LVEF <45%.
‡Reported as severity of dyspnea.
§88% of patients had severe HF (NYHA class III or IV).||Heart failure reduced ejection fraction.
¶Heart failure preserved ejection fraction.
**Dilated cardiomyopathy.
††Atherogenic dyslipidemia.
‡‡Chronic renal insufficiency (>177 μmol/L/>2.0 mg/dL or on dialysis.
§§Chronic renal failure/insufficiency.||||Atrial fibrillation or atrial flutter.
¶¶COPD or asthma.
***Chronic respiratory disease.
†††IV positive inotropes were administered as follows: dopamine (11%); dobutamine (10%); levosimendan (4%); noradrenaline (3%) and adrenaline (2%).
‡‡‡Data have been approximated.
§§§Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
¶¶¶Digoxin.
****CRT or ICD.
††††During hospitalization.
ADHERE, acute decompensated heart failure national registry; ADHERE-AP, acute decompensated heart failure registry-international Asia-Pacific; ARIC, Atherosclerosis Risk in Communities Study Community
Surveillance; ATTEND, acute decompensated heart failure syndromes registry; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; EHFS II, EuroHeart failure survey II; HF,
heart failure; ICD, implantable cardioverter defibrillator; IV, intravenous; KorAHF, Korean acute heart failure registry; LVEF, left ventricular ejection fraction; NR, not reported; NYHA, New York Heart Asso-
ciation; RAAS, renin angiotensin aldosterone system; Thai-ADHERE, Thai acute decompensated heart failure registry; TIA, transient ischemic attack; TSOC-HFrEF, Taiwan Society of Cardiology—Heart Failure
with reduced Ejection Fraction registry; UKNHFA, United Kingdom National Heart Failure Audit.
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Table 2. Baseline Characteristics and Clinical Treatment of Patients Enrolled in Regional Chronic HF Registries
Study ASIAN-HF16 Yu et al.40 CHART-141 KorHF42 CHF-REF43 CHART-241 HEARTS44 INTER-CHF*45 ADHERE9
EHFS II34/
UKNHFA35
Geography
(time frame)
11 countries
in Asia (2012–2015)
China
(2000–2010)
Japan
(2000–2004)
Republic of Korea
(2004–2009)
China
(2005–2009)
Japan
(2006–2010)
Dubai (2011–2012) 4 countries in Asia
(2012–2014)
United States
(2001–2004)
Europe/United Kingdom
(2004–2005)/(2014–2015)
Patients (n) 5276 12,450 1006 1527 2154 3676 504 2661 159,168 3580/56,915 cases
(N = 41,461)
Mean age(y) 60 62 69 69 64 70 63 60 72 70/78
Mal (%) 78 58 64 56 79 66 65 59 48 61/55
Mean LVEF (%) 28 (median) NR 50 29 37 56 NR NR 38 38/NR
LVEF <40 (%) 100 NR 54† 100 100 37† 54 59‡ 51 66§/NR
Known HF history 64.1|| NR NR 31 NR NR 82 28|| 76 63/NR
NYHA I/II/III/IV (%) 13/52/29/6 <1/23/50/ 27 NR/78/21/1 NR/NR/60/60¶ 0/41/34/25 NR/86/14/1 NR 13/45/29/13 NR NR/NR/19/45/37
Etiology (%)
Ischemic heart disease 47 28 27 40 NR 48 NR 48 58 54/51** and 40††
Valvular heart disease NR 18 NR 13 NR NR NR 13 NR 34/23** and 33††
Hypertensive NR 32 NR NR NR NR NR 14 NR 11/NR
Cardiomyopathy NR 27 33 22 NR 18 NR 10 NR 19/NR
Comorbidities (%)
Hypertension 52 NR 46 42 57 87 72 59 74 63/52** and 61††
Dyslipidemia NR NR 16 NR 24 78 23 26 NR NR/NR
Diabetes mellitus 40 NR 19 31 17 35 66 28 NR 33/33** and 33††
Chronic kidney disease NR NR NR 7‡‡ NR NR NR 7 30‡‡ 17‡‡/NR
Atrial fibrillation 18 NR 42 21§§ 16 42 21 NR 31 39§§/21** and 22††
COPD 8‖‖ NR NR 3 23 NR 17¶¶ NR 31¶¶ 19/17** and 19††
Previous stroke or TIA 6 NR NR 8 5 NR 13 10 NR 13/NR
Medication (%)
RAAS inhibitors 75 51 69 68 66 73 73 68 55*** 80/91**
β-blockers 79 44 29 41 68 51 81 61 58 61/86**
Aldosterone antagonists 59 53 19 38 75 27 49 44 16 48/52**
Diuretics 82 69 77 NR 74 56 91 62 65 90/98**
Digitalis NR 48 49 NR 58††† 25 7 28 19††† 31/23**†††
Calcium channel blockers NR NR 29 NR 46 38 15 NR 11 15/NR
Statins NR NR NR NR 43 36 67 NR 47 42/NR
ICD 14‡‡‡ NR 1.6‡‡‡ NR 2.2‡‡‡ 2.8‡‡‡ NR NR 5.4§§§ 1.2§§§/NR
CRT 14‡‡‡ NR 1.6‡‡‡ NR 5.8 2.8††† NR NR NR 2.7§§§/NR
*INTER-CHF was conducted in 16 countries across Africa, Asia, Middle East and South America (only data for Asia are presented in the table).
†LVEF <50%.
‡41% of patients had preserved ejection fraction (defined as LVEF ≥50%).
§LVEF <45%.
‖Previous hospitalization for HF (in past year for INTER-CHF).
¶Reported as 60% (NYHA class III–IV).
**Heart failure reduced ejection fraction.
††Heart failure preserved ejection fraction.
‡‡Chronic renal insufficiency.
§§Atrial fibrillation or atrial flutter.
‖‖Chronic respiratory disease.
¶¶COPD or asthma.
***Total calculated percentage of patients treated with angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers and renin inhibitors.
†††Digoxin.
‡‡‡CRT-D or ICD.
§§§During hospitalization.
ASIAN-HF, Asian Sudden Cardiac Death in Heart Failure; CHART, Chronic Heart Failure Analysis and Registry in the Tohoku District; CHF-REF, Chinese Chronic HF with reduced ejection fraction; HEARTS,
Heart Function Assessment Registry Trial in Saudi Arabia; INTER-CHF, INTERnational Congestive Heart Failure; other abbreviations as in Table 1.
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Asia-Pacific16,40–45 compared with patients enrolled in regis-
tries in the United States (ADHERE)9 and Europe (EHFS
II/UKNHFA).34,35 In general, patients were younger than those
in Western countries, as shown in the recent Asian Sudden
Cardiac Death in Heart Failure (ASIAN-HF) and
INTERnational Congestive Heart Failure (INTER-CHF) reg-
istry studies, in which mean age was 60 years.16,45 The majority
of patients with HF in the Asia-Pacific were male and aside
from 3 studies that recruited patients with a left ventricular
(LV) ejection fraction (LVEF) <40% only,16,42,43 the preva-
lence of HFrEF was 37% to 59% (Table 2). Furthermore,
patients with HF in regional registries were predominately
New York Heart Association class II/III.16,40–45
Ischemic heart disease was the major cause of HF in Asia-
Pacific populations (27%–48%), which is not too dissimilar
to that observed in Western populations (40%–58%).9,16,34,35,40–42,45
Despite some inconsistencies, comorbidities such as hyper-
tension and diabetes were highly prevalent in Asian patients
with HF (Table 2).16,41–45 Notably, some registry populations
(Heart Function Assessment Registry Trial in Saudi Arabia
[HEARTS]) were highly heterogeneous, containing subpopu-
lations from other regions and ethnic groups.44
Several global HF trials have examined geographic varia-
tions in clinical profile, management, and postdischarge
outcomes.46,47 Similar to the registry data, notable differ-
ences were recorded in the Prospective Comparison of
Angiotensin Receptor Neprilysin Inhibitor with Angiotensin-
Converting Enzyme Inhibitor to Determine Impact on Global
Mortality and Morbidity in Heart Failure (PARADIGM-
HF) trial for patient age (58 years in the Asia-Pacific and 65–
68 years in the United States/Western Europe); furthermore,
evidence-based therapies were most frequently used in Western
regions.47 Of note, this study found that the risk of death was
greater in the Asia-Pacific compared with North America.
A Focus on HFpEF
Despite clear guidance on the definition, diagnosis, and treat-
ment of HFrEF vs HFpEF,13,14 there are limited epidemiological
data on HFpEF in Asia-Pacific populations. The majority of
data is accessible through chronic HF registries, predomi-
nately in Japanese populations (eg, Chronic Heart Failure
Analysis and Registry in the Tohoku District [CHART]
studies). In these studies, the prevalence of HFpEF ranged
from 50% to 70% of the total HF population,48–50 higher than
that reported in multiethnic studies in Singapore (38.3%)51
and the INTER-CHF study of 5813 patients from Africa, Asia,
the Middle East, and South America (26% of the total pop-
ulation and 41% of 2661 Asian participants).45 Further, the
prevalence of HFpEF in Japan is higher than in Western reg-
istries (51%–69% vs 36%–47%, respectively),49,52–54 and
continues to increase (46% vs 63% in CHART-1 [2000–
2005] and CHART-2 [2006–2010], respectively),41 which is
in contrast to the modest increase in prevalence recorded in
the Framingham studies (33% in 2000 vs 39% in 2010).55 The
underlying reasons for the difference in rates are unclear at
present; however, lifestyle factors are likely to have a major
impact on disease prevalence (both HFpEF and HF in
general).41
Large-scale studies, including the Japanese Cardiac Reg-
istry of Heart Failure in Cardiology, have demonstrated that,
compared with patients with HFrEF, Japanese patients with
an LVEF >50% are significantly older and are more likely
to be female with higher systolic blood pressure and lower
heart rate.48,50 Patients with HFpEF were also more likely to
have a history of hypertension, renal failure, anemia, and atrial
fibrillation compared with patients with HFrEF, in which hy-
perlipidemia, sustained ventricular tachycardia or ventricular
fibrillation, and prior coronary revascularization were more
common.48 These data are supported by observations from
the multiethnic study in Singapore51 and in a population-
based study conducted in northeast China.56 In this latter study
of 2230 patients, the prevalence of HFpEF was greater in
women than men (4.9% vs 1.8%, respectively; P < .01) and
increased with age in both sexes; furthermore, although men
with HFpEF had a higher prevalence of hypertension, obesity,
and history of heart disease, women with HFpEF tended to
have hypertension, history of stroke, hyperuricemia, and
reduced renal function.56
Several studies have reported that all-cause mortality in Jap-
anese patients with HFpEF is not significantly different to that
in patients with HFrEF (ranging from ~20% to 25% in both
populations).41,48,57 In contrast,Yap et al. reported a lower 2-year
all-cause mortality rate in patients with HFpEF compared with
patients with HFrEF in a broad spectrum of Asian ethnicities
(27% vs 37%, respectively).51 Encouragingly, data from the
CHART-2 study suggest that the 3-year incidence rates of all-
cause and CV deaths of patients with both HFrEF and HFpEF
are improving.41
Current HF Diagnostic and Treatment Patterns in
the Asia-Pacific
Our review of the epidemiological data for HF has re-
vealed considerable inter- and intraregional variations, which
include differences in the underlying causes of HF and the
prevalence of comorbidities within the region, the age of pa-
tients hospitalized for HF, and length of hospital stay between
Asia-Pacific and Western countries. Possible explanations
include genetic and disease-modifying factors (eg, risk factors
for CV disease and comorbidities), but also contrasting ap-
proaches to management.58,59 In the Asia-Pacific region overall,
the diagnosis of HF is usually made on clinical grounds. In
the ADHERE-AP registry, measurement of natriuretic peptide
levels was performed in few patients hospitalized for ADHF;
brain natriuretic peptide (BNP) was assessed in 7.8% and
N-terminal pro B-type natriuretic peptide (NT-proBNP) was
assessed in 8.5% of cases.29 Use of echocardiography was
higher; LV function was assessed in approximately one-
half of patients.29 In contrast, echocardiography was performed
in 94.5% of patients in the TSOC-HFrEF registry, and NT-
proBNP, BNP, and troponin levels determined in 22.7%,
32.4%, and 64.4% of cases, correspondingly.33 In the Korean
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HF registry, 76.6% and 79.8% of patients hospitalized for
ADHF were assessed for natriuretic peptide levels or LV func-
tion, respectively, to support a clinical diagnosis.42 In patients
with stable HF in the outpatient setting, assessment of LV
function is considerably lower. In Australian primary care
clinics, echocardiography was performed in approximately
22% and 64% of outpatients with a suspected or known di-
agnosis of HF, respectively.60
The use of intravenous diuretics to relieve volume over-
load in patients admitted to the hospital with ADHF in Asia-
Pacific registries was common (63%–96%), similar to the
ADHERE and EHFS II registries (87% and 84%, respec-
tively) (Table 1). Administration of intravenous nitrates and
use of inotropic agents in the region were higher than re-
ported in ADHERE, but comparable to EHFS II registries
(Table 1). In addition, more patients required mechanical ven-
tilation (8%–20%, compared with 3%–5% in the Western
registries). This suggests that patients admitted to the hos-
pital with ADHF in Asia-Pacific regions may present with more
clinically severe conditions.
Despite evidence that adherence to pharmacological treat-
ment guidelines results in improved clinical outcomes,61,62 the
reported use of pharmacotherapy is generally lower in Asia-
Pacific countries compared with patients with HF enrolled
in Western registries (Tables 1 and 2). There were fewer pa-
tients discharged on evidence-based HF treatment in Asia-
Pacific registries. The use of renin angiotensin aldosterone
system (RAAS) inhibitors ranged from 51% to 75% in the
region, lower than that reported in ADHERE (83%), EHFS
II (80%), and UKNHFA (91%) (Table 2).9,16,34,35,40–42,44,45
β-blocker use varied widely in Asia-Pacific registries (Table 2),
although recent data from ASIAN-HF (79%) and INTER-
CHF (61%) were more comparable to Western studies (61%–
86%) (Table 2).9,16,34,35,40–45 Of interest, higher proportions of
patients with HFrEF (90%) and HFpEF (83%) enrolled in the
Swedish HF Registry (2005–2012; N = 41,976), received
β-blockers,63 compared with other European studies, despite
limited evidence of the benefit of β-blockers in HFpEF.13
The use of aldosterone antagonists ranged widely through-
out the region. Low use (19%) was reported in the Japanese
CHART-1 study, which was comparable to 16% of patients
prescribed aldosterone antagonists before hospital admis-
sion in the Get With The Guidelines-HF registry in the United
States (2005–2014; N = 117,761);36 in other studies, re-
ported use ranged from 27% to 53%, which was comparable
with other Western registries (33%–59%).9,16,34,35,40–42,44,45 High
use of aldosterone antagonists (75%) was reported in the
Chinese Chronic HF with Reduced Ejection Fraction
(CHF-REF) study.43 Of note, the aldosterone antagonist spi-
ronolactone was primarily used because eplerenone is not
approved for use in many countries in the region.
A relatively higher proportion of patients (48%–58%) was
prescribed digitalis in China and Japan (according to CHART-
1, CHF-REF, and the large registry conducted in China by
Yu et al.),40,41,43 compared with other Asia-Pacific countries
(7%–28%).41,44,45 The role of digitalis in the treatment of HF
is less certain,13 and use is less common in the United States
and Europe, with 19% to 38% of patients reported to receive
digitalis in the ADHERE, Get With The Guidelines-HF, EHFS
II, and UKNHFA registries.9,34–36
In general, prescription of diuretics (mainly loop diuretics)
was similar between patients with HF in the Asia-Pacific
(56%–91%) and the United States and Europe (65%–98%;
Table 2). Device use (defibrillator, pacemaker, or cardiac
resynchronization therapy) was low in the region (2%–6%),
which was consistent with EHFS II (1%–3%),34 but lower than
that reported in more recent studies in Europe (use ranging
from 5% to 18%) and America (5.1%–5.4%).64,65 By con-
trast, device use was considerably greater in the ASIAN-HF
registry (14.3%).16
Recent data from a multiethnic Asian population indi-
cated that patients with HFpEF were less likely to receive
angiotensin-receptor-blockers/angiotensin-converting-
enzyme inhibitors (60% vs 74%), diuretics (78% vs 87%),
mineralocorticoid receptor antagonists (8% vs 22%), β-blockers
(50% vs 65%), and statins (61% vs 72%) than patients with
HFrEF (all P < .001).51 This was supported by Takada et al.,
who reported that Japanese patients with LVEF >50% were
less likely to receive RAAS inhibitors (70% vs 80%, P < .001),
loop diuretics (31% vs 57%, P < .001), aldosterone antago-
nists (14% vs 34%, P < .001), or β-blockers (40% vs 65%,
P < .001) than patients with LVEF <50%. The use of statins
was consistent in both populations in this study.50
Finally, treatment patterns across the Asia-Pacific region
vary not only by country but also by setting. In general, pa-
tients with HF managed by cardiologists in hospitals compared
with those managed by general practitioners in primary care
were more likely to be treated at target doses of RAAS in-
hibitors and β-blockers (Table 3).66–70
Progress Toward Improvements in Data Quality
and Management Practices in the Asia-Pacific
Epidemiological data from the Asia-Pacific region are rel-
atively limited compared with data from Western populations,
despite the existence of some registries. However, our review
of the epidemiological and treatment data available for the
region underlines the need to improve the quality of data col-
lected on patients as well as management practices to reduce
inequalities within and between countries.
Regional Studies
Available registry data indicate that patients with HF from
the Asia-Pacific represent a distinct population compared with
their Western counterparts (Tables 1 and 2). Clinical trials
provide the means to further capture and understand base-
line characteristics of patient populations across different
countries and regions. Although trial inclusion and exclu-
sion criteria may limit the generalizability to some extent, such
information would provide insights that could lead to im-
provements in local management practices. However, it is
widely recognized that patients from Asia-Pacific countries
are underrepresented in global HF clinical trials.71
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Table 3. Regional Management of Patients with HF in Primary Care vs at a Specialized Unit
Study Krum et al., 200166
JCARE-GENERAL
GP-HF67
JCARE-GENERAL
Hospital-HF67 Yao et al., 201168 Ho et al., 201469 Mao et al., 201470
Geography (time frame) Australia (1998) Japan (2004–2005) Japan (2004–2005) Australia (2006–2011) Australia (2006–2011) Taiwan (2010–2012)
Study design Prospective multicenter Prospective multicenter Prospective multicenter Retrospective analysis of
medical records at a
single center
Retrospective analysis of
medical records at a
single center
Prospective single center
Population Outpatients with known or
suspected HF presenting to
a primary care physician
Outpatients with stable HF
managed by primary care
physicians in general
practice
Outpatients with stable HF
managed by cardiologists
in hospital
Patients hospitalized
for HF
Patients with documented
HF attending a
multidisciplinary clinic
in tertiary hospital
Patients with documented
HF attending a
multidisciplinary clinic in
tertiary hospital
Patients (n) 2905 1405 1280 667 255 349
Mean age (y) NR 77 71 76 81 60
Male (%) NR 38 55 53 47 70
Assessment of LV function (%) 64 (known HF); 22 (suspected HF) NR NR 36 NR 100
LVEF <40 (%) NR NR NR 50* 43† 66‡
Medication (%)
RAAS inhibitors 59§ 51 69 58 97 92
β-blockers 12 18 38 35 93 77
Aldosterone antagonists 8 NR NR 12 NR NR
Diuretics 63 58 66 72 NR NR
Digitalis 31|| 41 45 19‡ NR NR
Calcium channel blockers 10 41 33 11 NR NR
Statins NR NR NR 22 NR NR
*LVEF <45%.
†Systolic HF.
‡Mao CT, Liu MH, Hsu KH, Fu TC, Wang JS, Huang YY, et al. Unpublished data.
§ACEI.
||Digoxin.
ACEI, angiotensin-converting-enzyme inhibitor; JCARE-GENERAL, Japanese cardiac registry of heart failure in general practice; LV, left ventricular; other abbreviations as in Table 1.
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Enrollment of Asian patients ranged from 1% to 27% in
recent landmark trials such as Metoprolol Randomized In-
tervention Trial in congestive Heart Failure (MERIT-HF),
Systolic Heart Failure Treatment with the If Inhibitor
Ivabradine Trial (SHIFT), Randomized Aldactone Evalua-
tion Study (RALES), Eplerenone in Mild Patients
Hospitalization And Survival study in Heart Failure
(EMPHASIS-HF), PARADIGM-HF, Heart Failure End-
point Evaluation of Angiotensin II Antagonist Losartan
(HEEAL), Aliskiren Trial on Acute Heart Failure Outcomes
(ASTRONAUT), and ASCEND-HF, in which white pa-
tients predominated.39,46,47,72 Other large HF trials, including
Studies of Left Ventricular Dysfunction Treatment (SOLVD-
T) and Candesartan in Heart failure: Assessment of Reduction
in Mortality and morbidity (CHARM)-Added, have not in-
cluded any Asian patients.59,72
There is an urgent need for increased representation of pa-
tients from Asia and the Pacific in future clinical trials and
international registries.71 However, important progress is being
made in this respect as evidenced by the initial patient char-
acteristics data from the ASIAN-HF registry of 5276 patients
with HFrEF from 11 countries (China, Hong Kong, India, In-
donesia, Japan, Malaysia, Philippines, Republic of Korea,
Singapore, Taiwan, and Thailand).16 Implementation of di-
agnostic tools in the region, specifically echocardiography,
which was shown to be underused on patients in ADHERE-
AP compared with data from Western registries,29,73 is being
examined. Furthermore, ASIAN-HF will explore the contro-
versy over sudden cardiac death and use of implantable devices
in the region. According to Western data, sudden cardiac death
accounts for ~50% of deaths in patients with HF 74; however,
some studies have suggested a lower incidence in Asian pa-
tients, and recent trials have provided inconclusive data on
the benefit of implantable devices.75–78 It is anticipated that
data from ASIAN-HF will address the ambiguity surround-
ing sudden cardiac death and device use in the region allowing
physicians to make informed decisions on treatment
intervention.73
Regionally specific data will also be generated as part of
the Asian Network for Translational Research and Cardio-
vascular Trials (ATTRaCT) initiative, which will investigate
the underlying CV disease pathophysiology of HF in Asia with
the aim of identifying target diagnostic tools and therapies.
Further regional trials of note include the Singapore Heart
Failure Outcomes and Phenotypes and Prospective Evalua-
tion of Outcome in Patients with Heart Failure with Preserved
Left Ventricular Ejection Fraction (PEOPLE) studies. These
are the first studies determining the epidemiology, out-
comes and inter-ethnic differences in patients with HFpEF
in Singapore (n = 1250) and New Zealand (n = 1073),
respectively.79
Data of relevance for the region will also be generated by
the International Registry to Assess Medical Practice with Lon-
gitudinal Observation for Treatment of Heart Failure
(REPORT-HF), a global, prospective, observational study that
will characterize patient outcomes following an index hos-
pitalization for HF.80 It is anticipated that approximately 20,000
patients with new-onset HF will be enrolled in >300 sites in
40 countries with a follow-up period of 3 years.
The studies discussed previously will significantly enhance
epidemiological data in the region; however, fundamental im-
provements to the number of Asian-Pacific patients represented
in global trials including clinical and observational studies
are essential to fully understand future regional trends and
the overall disease burden. Dedicated regional clinical trials,
designed specifically to account for patient characteristics and
clinical practices may also be warranted.71 One such example
is the ongoing RELAXin in Acute Heart Failure in Asia
(RELAX-AHF-ASIA) trial, which has been designed to
account for specific management pathways for acute HF in
the region.81
Several barriers to patient enrollment currently exist, in-
cluding (1) poor awareness of HF and knowledge of the clinical
trial process, (2) reluctance to participate due to cultural/
social beliefs, and (3) poor access to hospitals/medical centers
(particularly for rural/remote patients). Strategies to improve
patient education would be effective in tackling the first 2 bar-
riers; the third barrier would most likely require intervention
by organizations with the medical sphere to improve local
infrastructure.
In parallel, improvements to study centers throughout the
region will be required to support increased numbers of en-
rolled patients. These include (1) enhanced medical and
administrative resources in local academic centers (eg, avail-
ability of diagnostic tools and trained support staff), (2)
increased number of participating centers in global trials, (3)
improved recognition of centers currently participating in
global trials, and (4) closer relationships between academic
establishments and pharmaceutical organizations (effective-
ly demonstrated by The Agency for Science, Technology and
Research and The National University Heart Centre,
Singapore).79 A coordinated effort on behalf of physicians,
academic establishments, pharmaceutical companies, and local
government will be required to successfully accomplish these
goals.
Differences between Regional Guidelines and European
Society of Cardiology (ESC) or American College of
Cardiology Foundation (ACCF)/AHA Guidelines
Many countries in the Asia-Pacific region have published
practical guidelines on the diagnosis and treatment of HF to
drive improvements in management practices.82–89 These guide-
lines are based mainly on evidence derived from clinical trials
conducted in Europe and the United States2; as a result, guide-
lines published by Asia-Pacific countries are somewhat
overlapping.82,83,85,86,88–90
Although regional guidelines are largely consistent with
ESC and ACCF/AHA guidelines in terms of pharmacolog-
ical therapy, varying emphases are placed on wider
management aspects. The Japanese Circulation Society guide-
lines (published in 2013), along with a simple set of guidelines
for chronic HF, emphasize the importance of determining
targets in the treatment and management of patients.89
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In China, the guidelines (published in 2014) emphasize the
usefulness of BNP and NT-proBNP in the diagnosis and eval-
uation of patients with HF and the importance of optimizing
standard medical therapy for 3 to 6 months before implan-
tation of a cardiac resynchronization device, the
recommendation of which has been updated to include pa-
tients with New York Heart Association class II HF and a left-
branch bundle block pattern QRS width ≥150 ms. Australian
guidelines published in 2011 highlight evidence to support
nonpharmacological management (eg, benefits of regular phys-
ical activity) alongside pharmacological management of
patients with HF.90
Malaysian guidelines (published in 2014) provide similar
recommendations to those for China, but in addition address
HF in patients who are pregnant, as well as in infants and
children, which are patient groups rarely mentioned in other
guidelines.85 The need for a multidisciplinary approach to the
management of patients with HF is also highlighted. Fur-
thermore, in Singapore, HF guidelines published in 2004
provide recommendations not only for health care profes-
sionals on diagnostic approaches, pharmacological, and surgical
therapy (including mechanical devices),87 but also have pub-
lished detailed guidelines for clinical pharmacists88 with
information on therapy initiation, titration and how to monitor,
prevent, and manage possible side effects.
Finally, the Taiwan Society of Cardiology guidelines (pub-
lished in 2012) recognize that social and ethnocultural
differences between Chinese and Western populations may
confound the management of Chinese patients with HF.85 For
instance, recommendations regarding the use of warfarin
suggest that the maintenance dose proposed in Western guide-
lines may not be suitable for Taiwanese patients with HF as
a result of interindividual and interethnic differences.85 This
should also be considered by other Asian countries. However,
although detailed recommendations for cardiac rehabilita-
tion and palliative care are provided, recommendations are
not accompanied by classifications and levels of evidence to
guide clinical decision making, as in the ESC and ACCF/
AHA guidelines.
Multidisciplinary Disease Management Programs
A key feature of current ESC and ACCF/AHA guidelines
is the focus on multidisciplinary disease management
programs,13,14 which have been shown to reduce hospitaliza-
tion, improve quality of life, and prolong survival,91–95 yet are
mentioned in few regional guidelines.85,86,88–90
In the Asia-Pacific, preliminary evidence suggests that mul-
tidisciplinary disease management programs are effective in
reducing all-cause mortality and HF-related rehospitalizations
in high-density populations with nationalized health care and
easy access to cardiologists.70 Additionally, there are several
hospital-based HF clinics that currently offer various out-
reach services (eg, home visits, telephone support). Using
telephone support and telemetry provides the opportunity to
advise patients with symptoms to seek immediate help, al-
lowing for earlier intervention, which may reduce or prevent
hospital admissions and all-cause mortality.96 However, there
are very few specialized clinics in the community, resulting
in limited access to specialists and additional resources that
are more easily accessible in hospitals. Home visits or home-
based HF clinics have been shown to reduce recurrent hospital
stays and are associated with significantly less total health
care expenditure per quality-adjusted life years compared with
community-based intervention.97
Limitations
This is a narrative review of currently published data, in-
cluding observational registry studies, controlled trials, and
treatment guidelines. As is typical with such publications, dis-
cussions include historical data and are somewhat limited to
methodological flaws introduced in the reviewed studies. More-
over, there is a potential for bias resulting from lack of a clear
systematic methodology. However, in the current paper, the ma-
jority of articles included were published after 2010 and, of
particular note, comparison of key findings (Tables 1 and 2)
are based on registry data from heterogeneous sources. A sys-
tematic review could have provided a more reliable and accurate
picture of heart failure in the Asia-Pacific compared with
Western regions and may have identified common method-
ological weaknesses and errors in the reviewed data.
Nevertheless, given the heterogeneous nature of the studies dis-
cussed, a narrative approach is considered to be of most value.
Summary and Conclusions
HF is a global health care problem, a leading cause of mor-
bidity and mortality in the Asia-Pacific, and has recently been
described as a “pandemic.” 20 Analysis of recent clinical trials
and disease registries highlight several regional trends: (1) pa-
tients with HF in the Asia-Pacific are younger and present with
more severe signs and symptoms of HF than those of Western
countries; (2) ischemic cardiomyopathy, valvular heart disease,
hypertension, and diabetes are common etiological and comorbid
factors that will have a greater impact on health care systems
in the future; (3) patients receive lower-than-recommended levels
of treatment despite the existence of local clinical guidelines;
and (4) intraregional variation exists. Although current ongoing
observational studies, including ASIAN-HF, which has re-
cently highlighted the significant heterogeneity among Asian
patients with HFrEF,16 will address the lack of regional epi-
demiological data and positively influence local clinical
guidelines, a significant effort will be required to address the
underrepresentation of Asian-Pacific patients in global trials.
Further resources are needed to better characterize patients, drive
improvements in local clinical practice, and inform local guide-
lines to improve the outlook for patients in the region.
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